Update on microbicide research and development-seeking new HIV prevention tools for women

European Journal of Medical Research

PE Kaptur¹  T Mertenskoetter¹ 

[1] International Partnership for Microbicides, Silver Spring, MD, USA 20910

关键词: vaginal ring;    vaginal gel;    antiretrovirals;    pre-exposure prophylaxis (PrEP);    HIV prevention;    microbicides;   

Others  :  829234
DOI  :  10.1186/2047-783X-16-1-1

 received in 2010-10-01, accepted in 2010-09-23,  发布年份 2011

【 摘 要 】

Women and girls are especially vulnerable to HIV infection in sub-Saharan Africa, and in some of those countries, prevalence among young women can be up to 3 times higher than among men of the same age. Effective HIV prevention options for women are clearly needed in this setting. Several ARV-based vaginal microbicides are currently in development for prevention of HIV transmission to women and are discussed here. The concept of pre-exposure prophylaxis for the prevention of HIV transmission to women is introduced.

【 授权许可】

   
2011 I Holzapfel Publishers

【 参考文献 】

• [1]AIDS epidemic update 2009 Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009. UNAIDS/09.36E/JC1700E, November 2009
• [2]Gouws E, Stanecki KA, Lyerla R, Ghys PD: The epidemiology of HIV infection among young people aged 15-24 years in southern Africa. AIDS 2008, 22(Suppl 4):S5-16.
• [3]Chandran P, Kabir SN: Dual action microbicides: reappraisal of their roles in contraceptive research. Reprod Biomed Online 2010, 20(1):103-13.
• [4]Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, MukengeTshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M, COL-1492 Study Group: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360(9338):971-7.
• [5]Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008, 3(1):e1471.
• [6]Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D, CS Study Group: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008, 359(5):463-72.
• [7]Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9654):1977-87.
• [8]Morris GC, Lacey CJN: Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 2010, 23(1):57-63.
• [9]Nuttall J: Microbicides in the prevention of HIV infection: current status and future directions. Drugs 2010, 70(10):1231-43.
• [10]Friend DR: Pharmaceutical development of microbicide drug products. Pharm Dev Technol 2009, 1-20.
• [11]Romano J, Malcolm RK, Garg S, Rohan LC, Kaptur PE: Microbicide delivery: formulation technologies and strategies. Curr Opin HlV AIDS 2008, 3(5):558-66.
• [12]Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in Women. Sciencexpress 2010, 1-13.
• [13]Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW: Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010, 55(2):161-9.
• [14]Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, Romano J: Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010, in press.
• [15]Nel A, Kamupira M, Hetro C, Nuttall J, Romano J: Safety and pharmacokinetics trial of dapivirine matrix vaginal ring. 18th International AIDS Conference, Vienna, Austria 2010. #PE0391
• [16]Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, Temmerman M, Verstraelen H, Van Bortel L, Weyers S, Mitchnick M: Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009, 25(5):1-6.
• [17]Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy HIV-negative women. AIDS 2009, 23(12):1531-8.
• [18]Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, Romano J: Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009, 51(4):416-23.
• [19]Van't Klooster G, van der Geest R, Gille D: Parmacokinetics, tolerability and safety of multiple oral doses of TMC120 (R147681) in 32 healthy subjects. Tibotec Pharmaceuticals Ltd. Trial No. TIBO-0001-104, Report No. TMC120-C104-CRR 2004.
• [20]Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP: Protection of Rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 coreceptor. [http://www.retroconference.org/2010/Abstracts/39821.htm] webciteJ Infect Dis 2010, 202(5):739-44. Accessed on September 28, 2010
• [21]Turville SG, Aravantinou M, Miller T, Kenney J, Teitel-baum A, Hu L, Chudolij A, Zydowsky TM, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M: Efficacy of Carraguard®-based microbicides in vivo despite variable in vitro activity. PLoS One 2008, 3(9):e3162.
• [22]Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol KM, Li J, Miller T, Robbiani M, Maguire RA, Buckheit RW Jr, Hartman TL, Phillips DM: Car-rageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007, 34(1):9-14.
• [23]Nonclinical Laboratory Studies: PC-1005 Gel (Car-rageenan with Added MIV-150 and Zinc Salts) [http://www.popcouncil.org/projects/285_NonclinLabPC1005.asp] webcitePopulation Council websiteAccessed on September 27, 2010
• [24]Nonclinical Laboratory Studies: Vaginal Rings Loaded with MIV-150 [http://www.popcouncil.org/projects/286_NonclinLabMIV150Ring.asp] webcitePopulation Council websiteAccessed on September 27, 2010
• [25]Nonclinical Laboratory Studies: Microbicide Formulation and Delivery [http://www.popcouncil.org/projects/285_NonclinLabPC1005.asp] webcitePopulation Council websiteAccessed on September 27, 2010
• [26]Bagnarelli P, Menzo S, Manzin A, Giacca M, Varaldo PE, Clementi M: Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. J Med Virol 1991, 34(2):89-95.
• [27]Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV: The prognostic value of cellular and serologic markers in infection with human immunod-eficiency virus type 1. N Engl J Med 1990, 322(3):166-72.
• [28]Garg AB, Nuttall J, Romano J: The future of HIV micro-bicides: challenges and opportunities. Antiviral Chem Chemother 2009, 19(4):143-50.
• [29]Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, Tillman SN, van der Straten A: Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav 2009, in press. doi: 10.1007/s10461-009-9635x
• [30]Nel AM, Lambert A, Isaacs M, Albertse M, Coetzee L: Daily monitored adherence as a possible adherence enabler in microbicide trials. Microbicides 2010 -- Building Bridges in HIV Prevention, Pittsburgh, PA, USA 2010, Abstract #58.
• [31]Schwartz JL, Rountree R, Kashuba A, Brache V, Creinin M, Poindexter A, Kearney B: A multi-compartment, single and multiple dose pharmacokinetic study of the candidate vaginal microbicide 1% tenofovir gel. 5th IAS Conference of HIV, Pathogenesis, Treatemtn and Prevention, Cape Town, South Africa 2009, Abstract No. LBPEC03.
• [32]Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Just-man J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L, HPTN 050 Protocol Team: Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006, 20(4):543-51.
• [33]Cutler B, Justman J: Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008, 8(11):685-97.
• [34]Creinin MD, Meyn LA, Borgatta L, et al.: Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008, 11(2 Pt 1):267-277.
• [35]Lete I, Doval JL, Perez-Campos E, et al.: Factors affecting women's selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception 2007, 76:77-83.
• [36]Kamali A: What is new in HIY/AIDS research in developing countries? Trop Med Int Health 2010, 15(8):975-80.
• [37]Grant RM: Antiretroviral agents used by HIV-uninfected persons for prevention: pre-and postexposure prophylaxis. Clin Infect Dis 2010, 50(Suppl 3):S96-101.
• [38]Underhill K, Operario D, Skeer MR, Mimiaga MJ, Mayer KH: Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2010, 55(1):8-13.
• [39]Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, the iPrEx Study Team: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, in press.